Receptor tyrosine kinase MET (c-MET) has received considerable attention as a potential target for gastric cancer (GC) therapy and a number of c-MET inhibitors have been developed. For successful drug development, proper preclinical studies especially using patient derived cancer cell lines are very important. We profiled MET and MET-related characteristics in 49 GC cell lines to utilize them as models in preclinical studies of GC. Forty-nine cell lines were analyzed for genetic, biological, and molecular status to characterize MET and MET-related molecules. Four c-MET inhibitors were tested to elucidate the dependency on MET pathway in the 49 GC cell lines. Six of 49 cell lines were MET amplified with overexpression of c-MET and p-MET. The variants of MET were not associated with c-MET expression or amplification. Hs746T showed an exon 14 deletion in conjunction with MET amplification. The cell lines were divided into 6 MET amplified, 2 c-MET overexpressed, 2 hepatocyte growth factor (HGF) overexpressed, and 39 MET-negative subgroups. Except tivantinib, the c-MET inhibitors showed higher inhibition (%) in MET amplified than in MET nonamplified cell lines that MET amplified cell lines showed MET pathway dependency. However, the c-MET overexpressed and HGF overexpressed cell lines showed moderate dependency on MET pathway. Well-characterized cell lines are very important in studying drug development. Our 49 GC cell lines had various characteristics of MET and METrelated molecules and MET pathway dependency. These provide a promising platform for development of various RTK inhibitors including c-MET inhibitors.
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Gastric cancer (GC) is the second most prevalent cancer, and the outcome of metastatic GC is very poor. Patients with metastatic GC have 8-12 months median survival despite use of chemotherapy.
1,2 Therefore, targeted agents are being developed to improve the survival rates and outcomes of GC patients. Studies targeting receptor tyrosine kinases (RTKs) have been actively pursued. RTKs, including human epidermal growth factor receptor 2 (HER2), c-MET and epidermal growth factor receptor (EGFR) are overexpressed or amplified in cancer cells, and their constitutive activation causes signaling pathway-related cell survival, proliferation and invasion.
Although trastuzumab-an HER2 targeted agent-is commonly used to treat HER2-positive patients, the incidence of HER2 positive is only 10% in GC patients. Therefore, novel molecular targets are required to treat more GC patients.
3
MET amplification is present in 4-5% of GC patients and is associated with poor outcome and significantly shorter median survival. 4 ,5 c-MET inhibitors are classified into two amplification in preclinical studies. 6, 7 However, they all have failed in clinical trials to show significant efficacy in GC patients. Therefore, identifying proper GC subgroups that are sensitive to c-MET inhibitors is important for the development of treatments. There is a need to define the accurate cutoff of biomarker levels using more reliable assays for select patients, and to develop new types of c-MET inhibitors. Various strategies have been developed to improve the efficacy of c-MET inhibitors. For example, a mixture of two monoclonal antibodies against c-MET (Sym015) has also been developed. 8, 9 In addition to targeting MET, downstream molecules have also been targeted and immunotherapy drugs are under development.
Human cancer cell lines have been used to evaluate the effects of drugs and their mechanism of action. Cell lines are easy to use, and generally reflect the biological characteristics of the original tumor. However, there are some disadvantages of using cell lines, including the loss of heterogeneity and the inability to mimic the unique environment of the tumor. Despite these disadvantages, cell lines are routinely used in preclinical research. 10, 11 Here, we investigated the genetic, molecular, and biological characteristics related to MET and also screened 49 GC cell lines for the sensitivity to c-MET inhibitors to determine whether these cell lines could be reliable for studying MET. This study provided the foundation for further studying MET-related pathways and c-MET inhibitor development in GC.
Materials and Methods

Cell lines
Forty-nine GC cell lines were used in this study. Three cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA), 10 cell lines were obtained from the Korean Cell Line Bank (KCLB, Seoul, Republic of Korea), 10 cell lines were purchased from the Japanese Cancer Research Resources Bank (JCRB, Osaka, Japan), and 26 cell lines were established by the Cancer Metastasis Research Center (CMRC) and from the Songdang Institute for Cancer Research (SICR), Yonsei University College of Medicine, Seoul, Republic of Korea from metastatic GC patients using ascites or pleural fluids. Cells were cultured in Eagle's Minimum Essential Medium (EMEM), Roswell Park Memorial Institute-1640 (RPMI-1640) medium, or Dulbecco Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum (Lonza, Basel, Switzerland), 100 units/mL of penicillin and 100 mg/mL of streptomycin (Lonza). Cultured cells were incubated at 378C in an atmosphere with 5% CO 2 .
Drugs
Four c-MET inhibitors were tested. Sym015 (a mixture of two monoclonal antibodies against c-MET) was provided by Symphogen (Symphogen A/S, Ballerup, Denmark). SAIT301 (a monoclonal antibody against c-MET) was provided by Samsung Advanced Institute of Technology (SAIT, Suwon, Republic of Korea). Tivantininb (a non-ATP, competitive small molecule kinase inhibitor against c-MET) and foretinib (an ATP, competitive small molecule kinase inhibitor against c-MET, RON, VEGFR2, etc.) were purchased from Selleckchem (Houston, TX). 5 Whole exome sequencing and RNA sequencing data analysis Whole exome sequencing (WES) and RNA sequencing data of the 49 GC cell lines were obtained from the genome database of Songdang Institute for Cancer Research (SICR), Yonsei University College of Medicine (Seoul, Republic of Korea). Briefly, copy number variants (CNVs) and single nucleotide variants (SNVs) were evaluated using WES data. The mRNA expression levels were measured in fragments per kilobase (kb) of exon model per million mapped reads (FPKM) without normalization.
Cell viability assay
Cells (8 3 10 3 ) were seeded into a 96-well plate. After 24 hr, they were treated with specific doses of the four c-MET inhibitors. Following 3 days of incubation, the Cell Counting Kit-8 (CCK-8; Dojindo, Kumamoto, Japan) solution was added and the plates were further incubated at 378C for 2 hr. The absorbance was measured at 450 nm and the samples were analyzed using CalcuSyn software (Biosoft, Cambridge, UK). The sensitivities of Sym015 and SAIT301 were measured by their inhibition rate (%) at the effective doses (100 nM and 5 mg/mL, respectively). Foretinib and tivantinib sensitivities were measured by their inhibition rate (%) at Cmax (0.08 mM and 5 mM, respectively).
12,13
Western blots
Total protein was extracted from the cell lines following the established protocol and 20 mg of protein was used for each western blot analysis. 14 The primary antibodies used in this study were 1:1000 dilutions of anti-c-MET antibody (Santa
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Cruz Biotechnology, Santa Cruz, CA), anti-p-MET antibody (Cell Signaling Technology, Danvers, MA), anti-EGFR antibody (Cell Signaling Technology), anti-HER2 antibody (Santa Cruz Biotechnology), anti-FGFR2 antibody (R&D Systems, Minneapolis, MN), anti-IGF1R antibody (Cell Signaling Technology) and a 1:5000 dilution of anti-c-Cbl antibody (Cell Signaling Technology). Peroxidase-conjugated antimouse or antirabbit antibodies were used as secondary antibodies. The protein blots were developed using X-ray films and enhanced chemiluminescent reagent (Amersham, Buckinghamshire UK). Data were normalized to a-tubulin (Sigma-Aldrich, St Louis, MO) and the intensity of proteins was semi-quantified using Image J software (NIH, Bethesda, MD).
Quantitative real-time PCR (qPCR) analysis
Genomic DNA (gDNA) was extracted following established protocols. 15 To determine the relative quantification of copy number variants of MET in 49 GC cell lines, we conducted TaqMan Each reaction was performed in duplicate. Human Genomic Control DNA (10 ng/ml) was used as a normal control (calibrator sample). Cycling conditions were 958C for 10 min and 40 cycles of 958C for 15 sec and 608C for 1 min. Each replicate was normalized to RNaseP to obtain a DCt and then averaged for each sample. All samples were then normalized to a calibrator sample to obtain DDCt.
Reverse transcription-PCR (RT-PCR) analysis
Total RNA was extracted using TRIzol V R reagent (Life Technologies, Carlsbad, CA) according to the manufacturer's instructions. To validate the exon 14 deletion of RT-PCR, RNAs were reverse transcribed using a superscript II firststrand synthesis system (Life Technologies). cDNA was synthesized and was run under the following conditions: the reactions containing PCR buffer, MgCl 2 , dNTP, primers, Taq-Gold and cDNA. Cycling conditions were 948C for 10 min, followed by 40 cycles 958C for 30 sec, 578C for 30 sec, 728C for 30 sec and then 728C for 10 min. The amplified products were separated on 1.2% agarose gel and GAPDH was used as house-keeping gene. The primer sequence was designed as follows: forward primer of exon 13 of MET (5 0 -TGA AAT TGA ACA GCG AGC TAA AT-3 0 ) and reverse primer of exon 15 of MET (5 0 -TTG AAA TGC ACA ATC AGG CTA-3 0 ).
Enzyme-linked immunosorbent assay (ELISA)
The lysate and conditioned media were prepared following the manufacturer's instructions. Cells (1 3 10 6 ) were seeded into a 6-well plate. After 24 hr, the cells were washed with phosphate-buffered saline (PBS) and replaced with serum free media. The next day, lysates and conditioned media were harvested to measure the concentration of HGF using the Quantikine HGF immunoassay (R&D Systems, Minneapolis, MN), according to the manufacturer's instructions. The amount of cell lysate was 20 mg and the amount of conditioned media was 5 mg.
Statistical analysis
Student's t tests and one-way ANOVA were used to assess the difference of the median of the 49 GC cell lines. Pearson's correlation coefficient V R was used to test the relationships between the DNA, mRNA and protein levels of MET using SPSS, version 21.0 software (SPSS Inc., Chicago, IL). A p value of <0.05 was considered statistically significant.
Results
Clinicopathological characteristics of the 49 GC cell lines
Among the 49 GC cell lines, 3 cell lines were from Caucasian patients and 46 cell lines were from Asian patients, including 36 Korean and 10 Japanese individuals. The origins of the cell lines were variable, with 12 of 49 cell lines from primary tumors and the others from metastatic sites, including 32 from body fluids and 2 from lymph nodes. Among 15 patients with available microsatellite instability (MSI) status from the Catalogue of Somatic Mutations in Cancer (COS-MIC) database, two patients showed MSI-high status. 16 In addition, there were two cell lines from Epstein-Barr virus (EBV)-infected cases.
17 Table 1 summarizes the clinicopathological features of the 49 GC cell lines and detailed characteristics of each cell line are listed in Supporting Information, Table S1 .
Profiles of MET and MET-related molecules
To evaluate the MET amplification status in the 49 GC cell lines, the CNV was analyzed using WES data (Fig. 1a, bar  graph ). There were 6/49 (12.2%) MET-amplified cell lines when the copy number of more than five copies was amplified (Fig. 1b) . 18 Copy numbers of the six amplified cell lines varied from 8.6 to 20.6 copies with a median of 13 copies as follows: SNU-620 (20.6 copies), YCC-34 (18.8 copies), Hs746T (13.6 copies), YCC-31(12.1 copies), MKN45 (12.1 copies) and SNU-5 (8.6 copies). The copy number of MET confirmed in the six amplified cell lines by qPCR had a median of 15.9 copies (range, 10.1-27.6) (Fig. 1a, line graph) . From the WES data, we detected genetic variants of MET in 4/49 (8.2%) cell lines, including SNU-638 (N375S), SNU-719 (D153A), YCCEL1/YCC-10 (H58L) and YCC-6 (R1382X) cell lines. N375S, D153A and R1382X were reported in the 1000 Genomes Project, while H58L was novel. 19 The schematic figure of variants in the 49 GC cell lines is illustrated in Supporting Information, Figure S1 . We also detected only one cell line with an exon 14 deletion in Hs746T (Fig. 1b) , which was confirmed by RT-PCR (Supporting Information, Fig. S2 ). MET amplification and the presence of variants were mutually exclusive except Hs746T with the exon 14 deletion. Finally, when we analyzed variants of MET-related downstream signaling molecules, there were no significant variants except one (YCC-29) with a phosphatase and tensin homolog (PTEN) deletion (Fig. 1b) .
According to the RNA sequencing data, MET mRNA was significantly overexpressed in the six MET-amplified cell lines (median FPKM value, 671; range, 209-1092) compared to nonamplified cell lines (median FPKM value, 36; range, 0.1-172) (Fig. 2a and Supporting Information, Fig. S3a ). We also observed six MET-amplified cell lines that overexpressed c-MET and p-MET (Y1234/1235) protein as determined by western blot (Fig. 2b and Supporting Information, Fig. S3b ). In addition, c-MET expression by two cell lines (YCC-36, SNU-638) was similar to that of MET-amplified cell lines and they also overexpressed p-MET, so we considered them to be c-MET overexpressed cell lines. We observed that the CNV from WES data and qPCR data were significantly correlated, and DNA, mRNA and protein levels were correlated with each other (Supporting Information, Fig. S4 ).
Next, we screened the cell lines for the expression of cCbl, a negative regulator of c-MET. Most of the cell lines expressed various levels of c-Cbl. Notably, the MET-amplified cell lines, except Hs746T, had lower c-Cbl expression than the non-MET-amplified cell lines (Fig. 2b) . We also analyzed the mRNA and protein level of HGF, the ligand of c-MET. The HGF mRNA was significantly overexpressed in SNU-484 and IM95m cells (median FPKM values, 286.9; range, 21.4-552.5) compared to the other 47 cell lines (median FPKM values, 0; range, 0-0.14). The protein levels of intracellular and secreted HGF were quantified in cell lysates and conditioned media using ELISA. HGF was overexpressed both in lysates and conditioned media in 2/49 (4.1%) of the cell lines, SNU-484 and IM95m, which were not MET amplified or overexpressed. As shown in Figure 1b , 2 of 49 cell lines had HGF variants (YCC-38 and NUGC3). However, these variants did not associate with mRNA and protein expression changes (Fig. 2c) . In summary, we identified 10 MET pathway associated cell lines (six MET-amplified, two c-METoverexpressed, and two HGF-overexpressed cell lines) among the 49 GC cell lines. The characteristics of 10 cell lines are summarized in Supporting Information, Figure S5 .
Patterns of other RTKs in the 49 GC cell lines
Because RTKs are major components in cancer cell biology, we screened four other RTKs (EGFR, HER2, FGFR2 and IGF1R) by WES and western blot in the 49 GC cell lines. There were no IGF1R-amplified or -overexpressed cell lines. However, there were six HER2-amplified, two EGFRamplified and four FGFR-amplified cell lines that were mutually exclusive. The median copy number for HER2 in the amplified cell lines was 20.9 copies (range, 3.2-78.7), with 40.4 copies (range, 13.6-67.1) for EGFR and 62 copies (4.3-141.9) for FGFR2 (Fig. 3a) . The protein expression of each RTK was measured by western blot in 49 GC cell lines (Fig. 3b) . 
Biological characteristics related to the MET pathway in the 49 GC cell lines
Based on the results shown in Figures 1 and 2 , we divided the 49 cell lines into 4 subgroups with 6 MET-amplified cell lines, 2 c-MET-overexpressed cell lines, 2 HGF-overexpressed cell lines and 39 MET-negative cell lines. Although the invasiveness varied among the cell lines, the number of invaded cells in the MET-amplified cell lines (median, 213; range, 76-604) was higher than in the METnegative cell lines (median, 98; range, 0-1240). We next measured the cell doubling time (DT), which reflects the cell proliferation rate. The DT varied in each cell line, but with no differences among the subgroups and the tumorigenicity also varied among the cell lines, suggesting crosstalk among diverse pathways (Table 2 and Supporting Information, Fig.  S6 ). In summary, each cell line showed a unique genetic and biological phenotype, which could be used as a specific molecular marker model system for functional biological analysis.
Sensitivity of c-MET inhibitors in the 49 GC cell lines
To evaluate the c-MET pathway dependency in each cell line, we tested the sensitivity to c-MET inhibitors using two METtargeting antibodies (Sym015 and SAIT301) and two small molecules (foretinib and tivantinib). The sensitivity of each drug was analyzed by inhibition rate (%) in 49 GC cell lines and listed in order of copy number of MET as analyzed by WES (Fig. 4) . As predicted, the MET-amplified cell lines were more sensitive to c-MET inhibitors than the MET-negative cell lines. The inhibition rate (%) with Sym015 was significantly higher in the MET-amplified cell lines (median, 44.9; range, 22.5-68.2) than in the MET-negative cell lines (median, 8.3; range, 0-37.0) (p < 0.0001). The inhibition rate (%) with SAIT301 in the MET-amplified cell lines (median 47; range, 9.7-64.3) was significantly higher than in the MET-negative cell lines (median, 0; range, 0-23.6) (p < 0.0001). The inhibition rate (%) for foretinib in the MET-amplified cell lines (median, 46.7; range, 27.8-94.5) was also higher than in the MET-negative cell lines (median, 10.6; range, 0-57.2) (p < 0.0001). However, tivantinib inhibited cell proliferation regardless of MET status. Interestingly, two cell lines, SNU-484 and IM95m, which HGF overexpressed cell lines with low MET expression were sensitive to Sym015. The inhibition rate (%) with Sym015 in HGF overexpressed cell lines was similar with c-MET overexpressed cell lines (median, 37.9 vs. 35.8), an effect not seen with the other agents, except tivantinib ( Supporting Information, Fig. S7 ). Further studies are needed to determine the mechanism for the different sensitivity to Sym015 in HGF overexpressed cell lines.
Discussion
Because RTKs are major biological factors in cancer progression and treatment resistance, drugs that target RTKs have been developed to treat GC. Among the RTKs, c-MET has received considerable attention as a potential target for cancer therapy. To develop targeted agents for RTKs, preclinical studies have used cell lines, most of which were established from Caucasian patients. Because GC is more common in the Asian population, using cell lines derived from those patients could be more useful for the development of targeted agents based on the characteristics of Asian cancers. There have been several studies using Asian GC cell lines. 20, 21 However, the characterization of MET in Asian GC cell lines has not been studied. To the best of our knowledge, this is the first study of MET and MET-related profiling of GC cell lines.
Of the 49 GC cell lines established from 46 Asian cancer patients, 36 were established from Korean patients. Among the 49 GC cell lines, we confirmed that six cell lines (SNU-5, SNU-620, MKN45, YCC-31, YCC-34 and Hs746T) with MET amplifications overexpressed c-MET and p-MET. Moreover, all six MET-amplified cell lines were sensitive to both the antibody and small-molecule c-MET inhibitors. Our results confirmed that MET amplification predicts the sensitivity of c-MET inhibitors that identified in various cancer types. 6, 7 The variants of MET were not associated with the sensitivity of c-MET inhibitors, except for variant N375S, a germline polymorphism that is located in the Sema domain of c-MET that associated with loss of affinity to HGF. N375S variant frequently occurs in Asians and its biological role is unclear. In preclinical studies of lung cancer, the loss of binding affinity of c-MET to HGF by N375S variant was analyzed in silico and they showed N375S variant conferred resistance to SU11274, c-MET inhibitor. [22] [23] [24] However, our results suggested that SNU-638 with the N375S variant was more sensitive to c-MET inhibitors than the other cell lines which did not have that variant (Fig. 4) . It is not clearly known the biological role of N375S variant in cancer. Therefore, the association of sensitivity of c-MET inhibitors and variants should be further studied.
Because RTKs are significant targets in many cancers, we also evaluated the major RTKs in GC. Among the 49 GC cell lines, RTKs were amplified in 18 cell lines (36.7%), including the amplification of MET (n 5 6), HER2 (n 5 6), EGFR (n 5 2) and FGFR2 (n 5 4). The incidence of RTK amplifications in the cell lines was similar to that of GC patients, and the amplifications were mutually exclusive. 25 Most cell lines obtained from the SICR and CMRC were established before treatments with any of the RTK targeting agents were used. However, YCC-38, an HER2-amplified cell line, was established after trastuzumab (HER2 targeted antibody) treatment.
The c-MET pathway is activated by HGF binding, MET amplification/overexpression, and exon 14 deletion and it is negatively regulated by recruiting c-Cbl. The c-Cbl binds to c-MET when the Y1003 site is phosphorylated, and this then leads to degradation of p-MET (Y1003). 26 When we screened for the expression of c-Cbl in the GC cell lines, five of the six MET-amplified cell lines had lower c-Cbl expression compared to the relatively higher c-Cbl expression in MET-nonamplified cell lines. This suggests that MET amplification and low expression of c-Cbl act synergistically to activate the MET pathway. Interestingly, Hs746T had higher expression of c-Cbl than other MET-amplified cell lines. However, the expression of c-Cbl did not affect the status of MET because Hs746T was found to have an exon 14 deletion, which is associated with a deletion of the juxtamembrane domain of MET with the Y1003 site, resulting in the loss of interaction with c-Cbl. 27 There were two c-MET-overexpressed cell lines (YCC-36 and SNU-638) and two HGF-overexpressed cell lines (SNU-484 and IM95m). They showed a tendency of increased sensitivity to c-MET inhibitors. In particular, the two HGFoverexpressed cell lines, which were not MET-amplified oroverexpressed, were sensitive to c-MET inhibitors tested, especially Sym015. Further studies are ongoing to explore the mechanism of this HGF related sensitivity to Sym015. At the same time, finding specific predictive biomarkers of each c-MET inhibitor is under evaluation.
Among the four c-MET inhibitors tested, the sensitivity to tivantinib varied independently of MET status (median inhibition 49.9%, range 0-95.1%). In comparison, the median inhibition rate (%) for Sym015, SAIT301 and foretinib were 10.6%, 1.1% and 14.0%, respectively. Tivantinib has been reported to be a non-ATP-competitive inhibitor for c-MET, but there is evidence that c-MET is not its only target. It has been shown that tivantinib also inhibits microtubule polymerization and shows cytotoxicity in c-MET-dependent or -independent cells. 28 This could explain the various sensitivities of tivantinib in the 49 GC cell lines (Fig. 4 and Supporting Information, Fig. S8 ). Among the hot spot variants in the downstream pathways, there were PIK3CA variants in IM95m which were not related to c-MET inhibitor resistance, especially to Sym015, suggesting more dependency on the c-MET direct pathway (HGF overexpression), rather than downstream pathway. It is known that KRAS variant confer resistance to c-MET inhibitor and all 6 MET-amplified cell lines were KRAS wild type. 29 Preclinical studies using cell lines are very important for drug development. Cell lines could reflect the genetic and biological characteristics of the original tumor. The 49 GC cell lines used in our study showed RTK amplification similar to that of GC patients as we mentioned above. In our study, we determined the genetic, biological and molecular characteristics of MET and MET-related molecules in 49 GC cell lines.
The 49 GC cell lines reflected the genomic pattern of advanced GC patients with various biological and molecular characteristics. This is a genetic profiling as a preclinical model system for the application to drug screening and this could be useful for biomedical research, not only for understanding GC biology, but also for novel drug development. Along with this integrated genetic profiling, we screened MET-related molecules and sensitivity of c-MET inhibitors in this study. Furthermore, this profiling could be useful in various research studies of drug development.
